Using Nicotinamide Riboside to Lower Blood Pressure in Older Adults
Nicotinamide Riboside Supplementation for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
This study is testing if taking nicotinamide riboside can help lower blood pressure and improve artery health in older adults with high blood pressure.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 118 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | University of Colorado, Boulder Academic / other |
| Locations | 1 site (Boulder, Colorado) |
| Trial ID | NCT03821623 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of nicotinamide riboside supplementation on lowering systolic blood pressure and aortic stiffness in middle-aged and older adults aged 50-79 with elevated to stage-1 hypertension. The study employs a randomized, double-blind, placebo-controlled design over a period of three months. Participants will be assessed for changes in blood pressure and arterial stiffness, as well as the safety and tolerability of the supplement. The trial aims to provide a practical alternative to caloric restriction for managing hypertension in older adults.
Who should consider this trial
Good fit: Ideal candidates are middle-aged to older adults aged 50-79 with systolic blood pressure between 120 and 139 mmHg.
Not a fit: Patients with severe hypertension (systolic blood pressure <120 or ≥160 mmHg) or those currently on antihypertensive medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could offer a new, effective method for managing high blood pressure in older adults without the drawbacks of caloric restriction.
How similar studies have performed: Previous pilot studies have shown promising results with nicotinamide riboside supplementation in lowering blood pressure, indicating potential for success in this larger trial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ability to provide informed consent * Willing to accept random assignment to condition * Systolic blood pressure between 120 and 159 mmHg * Body mass index \<40 kg/m2 * Weight stable in the prior 3 months (\<2 kg weight change) and willing to remain weight stable throughout the study * Absence of other clinical disease as determined by medical history, physical examination, blood chemistries, ankle-brachial index, and 12-lead ECG at rest and during graded treadmill exercise * Ankle-brachial index \>0.7 * Total cholesterol \<240 mg/dL * Fasting plasma glucose \<126 mg/dL * Normal 12-lead ECG at rest and during graded treadmill exercise to fatigue Exclusion Criteria: * Systolic blood pressure \<120 or \>/= 160 mmHg * Currently taking antihypertensive medications * Other chronic medical condition (e.g., diabetes, chronic kidney disease, cancer) * Current smoker * Alcohol dependence or abuse * Uncontrolled thyroid disease or change in thyroid medication within previous 3 months * Abnormal blood pressure response to exercise (drop in SBP below resting pressure or SBP \>160 mmHg or DBP \>115 mmHg) * Regular vigorous aerobic/endurance exercise (\>4 bouts/weeks, \>30 min/bout at a workload \>6 METS)
Where this trial is running
Boulder, Colorado
- Integrative Physiology of Aging Laboratory — Boulder, Colorado, United States (Recruiting)
Study contacts
- Study coordinator: Daniel H Craighead, PhD
- Email: daniel.craighead@colorado.edu
- Phone: 303-492-7702
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.